Real-world safety profile of riluzole: a systematic analysis of data from the FAERS database and case reports

References

• Fehlings MG, Badhiwala JH, Ahn H, et al. Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Neurol. 2021 Feb [Epub 2020 Dec 22];20(2):98–106. doi: 10.1016/S1474-4422(20)30407-5
   PubMed Web of Science ®Google Scholar
• Fehlings MG, Nakashima H, Nagoshi N, et al. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. Spinal Cord. 2016 Jan [Epub 2015 Jun 23];54(1):8–15. doi: 10.1038/sc.2015.95
   PubMed Web of Science ®Google Scholar
• Sakurai H, Dording C, Yeung A, et al. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 Nov 1 Epub 2019 Jul 2;258:102–108. doi: 10.1016/j.jad.2019.06.065
   PubMed Web of Science ®Google Scholar
• Blyufer A, Lhamo S, Tam C, et al. Riluzole: a neuroprotective drug with potential as a novel anticancer agent (Review). Int J Oncol. 2021 Nov;59(5):95. doi: 10.3892/ijo.2021.5275
   PubMed Web of Science ®Google Scholar
• Hu Y, Gong J, Zhang L, et al. Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020 Jul;84:106601.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao X, He Y, et al. Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature. Expert Opin Drug Saf. 2022 Oct;21(10):1329–1336.
   PubMed Web of Science ®Google Scholar
• Tian X, Zheng S, Wang J, et al. Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review. Expert Opin Drug Saf. 2022 May 27; 1–6. doi: 10.1080/14740338.2022.2078301
   Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001 Oct;10(6):483–486. doi: 10.1002/pds.677
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002 Jan;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239–245. doi: 10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Borderías-Clau L, Garrapiz-López J, Val-Adán P, et al. Alta sospecha de toxicidad pulmonar por riluzol [Strong suspicion of lung toxicity due to riluzole]. Arch Bronconeumol. 2006 Jan;42(1):42–44. Spanish. doi: 10.1157/13083280
   PubMedGoogle Scholar
• Cassiman D, Thomeer M, Verbeken E, et al. Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. Neurology. 2003 Oct 28;61(8):1150–1151. doi: 10.1212/01.wnl.0000082385.33604.1d
   PubMed Web of Science ®Google Scholar
• González-Fernández C, Güell R, Anton A. Pulmonary toxicity by riluzole. Med Clin. 2017 Dec 20;149(12):561–562. English, Spanish. doi: 10.1016/j.medcli.2017.06.052
   PubMed Web of Science ®Google Scholar
• Saitoh Y, Miyazaki M, Arai N, et al. Pneumomediastinum while using mechanical insufflation-exsufflation after recovery from riluzole-induced interstitial lung disease. eNeurologicalsci. 2021 Feb 2;22: 100326. doi: 10.1016/j.ensci.2021.100326
   PubMedGoogle Scholar
• Saitoh Y, Aoshima Y, Mukai T, et al. Riluzole-induced interstitial lung disease is a rare and potentially life-threatening adverse event successfully treated with high-dose steroid therapy: case reports and review of the literature. J Neurol Sci. 2020 Mar 15;410:116650.
   PubMed Web of Science ®Google Scholar
• Takeshima S, Neshige S, Himeno T, et al. Riluzole-induced interstitial pneumonia in a case with amyotrophic lateral sclerosis. Rinsho Shinkeigaku. 2015;55(11):840–843. Japanese. doi:10.5692/clinicalneurol.cn-000763
   PubMedGoogle Scholar
• Kakuta T, Hirata H, Soda S, et al. Riluzole-induced lung injury in two patients with amyotrophic lateral sclerosis. Intern Med. 2012;51(14):1903–1907. doi: 10.2169/internalmedicine.51.6522
   PubMed Web of Science ®Google Scholar
• Rodrigo L, Moreno M, Calleja S, et al. Riluzole-induced acute pancreatitis. Am J Gastroenterol. 2001 Jul;96(7):2268–2269. doi: 10.1111/j.1572-0241.2001.03982.x
   PubMed Web of Science ®Google Scholar
• Ianiro G, Cammarota G, Milani A, et al. Moderately severe acute pancreatitis associated with riluzole. J Clin Gastroenterol. 2014 Jul;48(6):563.
   PubMed Web of Science ®Google Scholar
• Drory VE, Sidi I, Korczyn AD. Riluzole-induced pancreatitis. Neurology. 1999 Mar 10;52(4):892–893. doi: 10.1212/wnl.52.4.892
   PubMed Web of Science ®Google Scholar
• Falcão de Campos C, de Carvalho M. Riluzole-induced recurrent pancreatitis. J Clin Neurosci. 2017 Nov;45:153–154. doi: 10.1016/j.jocn.2017.08.032
   PubMed Web of Science ®Google Scholar
• Sorenson EJ. An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology. 2006 Dec 26;67(12):2260–2261. doi: 10.1212/01.wnl.0000249182.09143.20
   PubMed Web of Science ®Google Scholar
• Remy AJ, Camu W, Ramos J, et al. Acute hepatitis after riluzole administration. J Hepatol. 1999 Mar;30(3):527–530.
   PubMed Web of Science ®Google Scholar
• Weber G, Bitterman H. Riluzole-induced neutropenia. Neurology. 2004 May 11;62(9):1648. doi: 10.1212/01.wnl.0000123015.48097.9a
   PubMed Web of Science ®Google Scholar
• North WA, Khan AM, Yamase HT, et al. Reversible granulocytopenia in association with riluzole therapy. Ann Pharmacother. 2000 Mar;34(3):322–324. doi: 10.1345/aph.19153
   PubMed Web of Science ®Google Scholar
• Viallon A, Page Y, Bertrand JC. Methemoglobinemia due to riluzole. N Engl J Med. 2000 Aug 31;343(9):665–666. doi: 10.1056/NEJM200008313430918
   PubMed Web of Science ®Google Scholar
• Woolf A, Carstairs SD, Tanen DA. Riluzole-induced methemoglobinemia. Ann Emerg Med. 2004 Feb;43(2):294. doi: 10.1016/j.annemergmed.2003.08.012
   PubMed Web of Science ®Google Scholar
• Bodner T, Jenner C, Benke T, et al. Intoxication with riluzole in Huntington’s disease. Neurology. 2001 Sep 25;57(6):1141–1143.doi: 10.1212/wnl.57.6.1141
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3;330(9):585–591. doi: 10.1056/NEJM199403033300901
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996 May 25;347(9013):1425–1431. doi: 10.1016/s0140-6736(96)91680-3
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. ALS Study Groups I and II. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Mar;3(1):23–29.
   PubMed Web of Science ®Google Scholar
• Inoue-Shibui A, Kato M, Suzuki N, et al. Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study. BMC neurol. 2019 Apr 27;19(1):72. doi: 10.1186/s12883-019-1299-1
   PubMedGoogle Scholar
• Nitsche CJ, Jamieson N, Lerch MM, et al. Drug induced pancreatitis. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):143–155.
   PubMed Web of Science ®Google Scholar
• FOOD AND DRUG ADMINSTRATION(FDA). The label of riluzole［EB/OL]. Rockville: FDA, 2020 May 11. [2022 Dec 9]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020599s019lbl.pdf
   Google Scholar
• Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration. 2004 Jul;71(4):301–326. doi: 10.1159/000079633
   PubMed Web of Science ®Google Scholar
• McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019 May [Epub 2018 Nov 21];137(5):715–730. doi: 10.1007/s00401-018-1933-9
   PubMed Web of Science ®Google Scholar
• Lyon MS, Wosiski-Kuhn M, Gillespie R, et al. Inflammation, Immunity, and amyotrophic lateral sclerosis: i. Etiology and pathology. Muscle Nerve. 2019 Jan;59(1):10–22. doi: 10.1002/mus.26289
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Kato B, Mizushima Y, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with amyotrophic lateral sclerosis in respiratory failure. Respirology. 1999 Jun;4(2):185–187. doi: 10.1046/j.1440-1843.1999.00172.x
   PubMedGoogle Scholar